Clear All
11110 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50242-0933-01 50242-0933 Atezolizumab and hyaluronidase-tqjs Tecentriq Hybreza 1875.0 mg/15mL, 30000.0 U/15mL Immunotherapy Checkpoint Inhibitor PD-L1 Subcutaneous Sep 12, 2024 In Use
00597-0145-60 00597-0145 Nintedanib Ofev 150.0 mg/1, 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Oral Oct 17, 2014 In Use
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous Mar 18, 2022 In Use
59353-0220-10 59353-0220 Epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL, 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Nov 9, 2020 In Use
59353-0010-10 59353-0010 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL, 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Jun 18, 2018 In Use
55513-0206-01 55513-0206 Bevacizumab-awwb MVASI 100.0 mg/4mL, 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jun 1, 2018 In Use
68727-0745-05 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug 3, 2017 In Use
68727-0745-01 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug 3, 2017 In Use
68727-0745-02 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug 3, 2017 In Use
64842-0727-09 64842-0727 CEDAZURIDINE and DECITABINE INQOVI 100.0 mg/1, 35.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog + CDA Inhibitor Oral Aug 25, 2020 In Use
00597-0143-60 00597-0143 Nintedanib Ofev 100.0 mg/1, 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGFR, PDGFR, FLT3, CSF1R Oral Oct 17, 2014 In Use
67457-0481-01 67457-0481 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sep 1, 2012 Aug 31, 2016 No Longer Used
67457-0431-11 67457-0431 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sep 1, 2012 Aug 31, 2016 No Longer Used
45963-0607-56 45963-0607 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Mar 1, 2015 In Use
67457-0479-53 67457-0479 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sep 1, 2012 Aug 31, 2016 No Longer Used
45963-0607-55 45963-0607 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Mar 1, 2015 In Use
13668-0462-30 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Jun 30, 2017 In Use
13668-0462-01 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Jun 30, 2017 In Use
13668-0462-74 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Jun 30, 2017 In Use
13668-0453-30 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Jun 30, 2017 In Use
13668-0453-01 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Jun 30, 2017 In Use
54092-0063-01 54092-0063 Anagrelide hydrochloride Agrylin 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Mar 14, 1997 In Use
13668-0453-74 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Jun 30, 2017 In Use
42427-0002-60 42427-0002 Mechlorethamine Hydrochloride Valchlor 0.012 g/60g, 0.012 g/60g Chemotherapy Alkylating Agent Nitrogen Mustard Topical Oct 21, 2013 Oct 22, 2013 No Longer Used
69468-0151-20 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Mar 1, 2016 In Use

Found 11110 results — Export these results